LauriMBurroughsMD

Pediatric Hematology & Oncology • Seattle, WA

Assistant Professor, Pediatrics, University of Washington School of Medicine

Join to view full profile

Dr. Burroughs is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Burroughs' full profile

Already have an account?

Office
4800 Sand Point Way Ne
Seattle, WA 98105
Phone+1 206-987-2106

Education & Training

University of WashingtonFellowship, Pediatric Hematology/Oncology, 2001 - 2004
Indiana University School of MedicineResidency, Pediatrics, 1998 - 2001
University of Wisconsin School of Medicine & Public HealthClass of 1998

Certifications & Licensure

WA State Medical License 2001 - 2026
NC State Medical License 2022 - 2022
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

Total-Body Irradiation Followed By Cyclosporine and Mycophenolate Mofetil in Treating Patients With Severe Combined Immunodeficiency Undergoing Donor Bone Marrow Transplant Start of enrollment: 1997 Aug 11
Completed
Phase 1
Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant and Cyclophosphamide, Mycophenolate Mofetil, Tacrolimus, and Sirolimus in Treating Patients With Primary Immunodeficiency Disorders or Noncancerous Inherited Disorders Start of enrollment: 2006 May 24
Terminated
Phase 2
Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by a Donor Stem Cell Transplant in Treating Patients With Immunodeficiency or Other Nonmalignant Inherited Disorders Start of enrollment: 2006 Jun 01
Completed
Phase 2
Treosulfan and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Nonmalignant Inherited Disorders Start of enrollment: 2009 Jul 31
Completed
Phase 2
Natural History Study of SCID Disorders Start of enrollment: 2010 Sep 02
Enrolling by invitation
Patients Treated for SCID (1968-Present) Start of enrollment: 2011 May 15
Enrolling by invitation
Gene Transfer for X-Linked Severe Combined Immunodeficiency in Newly Diagnosed Infants Start of enrollment: 2016 Aug 17
Suspended
Phase 1, Phase 2
Patients Treated for Wiskott-Aldrich Syndrome (WAS) Since 1990 Start of enrollment: 2014 Feb 02
Completed
Patients Treated for Chronic Granulomatous Disease (CGD) Since 1995 Start of enrollment: 2014 Jun 01
Enrolling by invitation
Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant Diseases Start of enrollment: 2015 Feb 01
Terminated
Phase 1
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Thiotepa in Treating Patients With Non-malignant Disorders Start of enrollment: 2021 May 05
Recruiting
Phase 2
Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases Start of enrollment: 2020 Jun 16
Suspended
Phase 1, Phase 2
Conditioning SCID Infants Diagnosed Early Start of enrollment: 2018 Oct 22
Recruiting
Phase 2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

8 citations
Genotype, oxidase status, and preceding infection or autoinflammation do not affect allogeneic HCT outcomes for CGD.
Jennifer W Leiding, Danielle E Arnold, Suhag Parikh, Brent Logan, Rebecca A Marsh
Blood. 2023-12-14
69 citations
Excellent outcomes following hematopoietic cell transplantation for Wiskott-Aldrich syndrome: a PIDTC report
Lauri Burroughs, Aleksandra Petrovic, Ruta Brazauskas, Xuerong Liu, Linda M. Griffith
Blood. 2020-06-04
14 citations
Measuring the effect of newborn screening on survival after haematopoietic cell transplantation for severe combined immunodeficiency: a 36-year longitudinal study from...
Monica S Thakar, Brent R Logan, Jennifer M Puck, Elizabeth A Dunn, Rebecca H Buckley
Lancet. 2023-07-08

Journal Articles

Novel Lineage Depletion Preserves Autologous Blood Stem Cells for Gene Therapy of Fanconi Anemia Complementation Group A
Lauri M Burroughs, Pamela S Becker, Haematologica
Reduced Intensity Conditioning for Hematopoietic Cell Transplant for HLH and Primary Immune Deficiencies: BMT CTN 1204
Shalini Shenoy, K Scott Baker, Elizabeth O Stenger, Mary Eapen, Carl Allen, Lauri Burroughs, Philip Roehrs, Catherine M Bollard, Rabi Hanna, Jeffrey R Andolina, James ..., Blood

Abstracts/Posters

Comparison of Outcomes between HSCT Donor Sources for Pediatric Patients with Hematologic Malignancies
Lauri S Burroughs, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

From Bone Marrow to Mobilized Peripheral Blood Stem Cells: The Circuitous Path to Clinical Gene Therapy for Fanconi AnemiaClinically Relevant Abstract
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Grant Support

Nonmyeloablative Allografting For Immunodeficiency &Other Nonmalignant DisordersNational Heart, Lung, And Blood Institute2007–2010